Therefore, active components such as quercetin, kaempferol, beta-sitosterol, stigmasterol, and palmatine act through targets such as AKT1, MAPK1, HSP090AA1, and TP53 to jointly regulate signaling pathways such as pathways in cancer, lipid and atherosclerosis, PI3K-Akt signaling pathway, MAPK signaling pathway, and microRNAs in cancer to achieve CRA treatment efficacy. This evidence concerns the gene AKT1 and cancer.